Poop pills plus antibody: a new hope for stubborn gut infections?

NCT ID NCT03829475

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 19 times

Summary

This study tested whether adding a drug called bezlotoxumab to a fecal transplant (FMT) could better prevent repeat C. diff infections in people with inflammatory bowel disease (IBD). About 61 adults with both IBD and recurrent C. diff were randomly assigned to get FMT plus bezlotoxumab or FMT plus a placebo. Researchers tracked them for 3 months to see who got another C. diff infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

Conditions

Explore the condition pages connected to this study.